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Vascular complicationa b s t r a c t
The incidence of thyroid dysfunction in diabetic patients is higher than that of the general population.
Undiagnosed thyroid dysfunction may affect the metabolic control and enhance cardiovascular, and other
chronic complication risks in diabetic patients. Few studies have examined the relationship between sub-
clinical hypothyroidism (SCH) and vascular complications of type 2 diabetes. Objectives: To find out the
relationship between SCH and vascular complications in patients with Type 2 diabetes. Subjects and
Methods: Our cross sectional study included 110 patients with type 2 DM (45 males and 65 females)
who were followed at the Diabetes outpatient Clinics in the state of Kuwait during 6 months period.
All patients subjected to complete clinical and laboratory data, including thyroid function tests, total
cholesterol (TC), triglyceride (TG), HDL-C, LDL-C, urinary albumin, fundus examination, ECG, and
Glycosylated hemoglobin. Results: Among 110 patients, 21 (19.1%) Patients had SCH. Patients with SCH
were more significantly older, with longer duration of diabetes, higher HbA1c, total cholesterol and
LDL-C than euthyroid group. However, gender (p = 0.076), BMI (p = 0.092), and smoking (P = 0.715) were
not significantly different between the SCH and euthyroid groups. The SCH group had a higher prevalence
of dyslipidemia (p = 0.017), diabetic nephropathy (p = 0.003) diabetic retinopathy (p = 0.004) and IHD
(p = 0.011) than the euthyroid group while no significant difference in the prevalence of diabetic neu-
ropathy (p = 0.420). Conclusions: SCH is a common endocrine disorder in patients with Type 2 diabetes.
It could be associated with a higher prevalence of vascular complications in type 2 diabetes. We could
not prove a relation between SCH and diabetic neuropathy.
 2016 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Subclinical hypothyroidism (SCH) is defined as an asymp-
tomatic state that is characterized by high serum concentration
of thyroid-stimulating hormone (TSH) and a normal serum concen-
tration of thyroxine.1 The incidence of thyroid dysfunction in dia-
betic patients is higher than that of the general population and
up to a third of patients with type-1 diabetes (T1DM) and 4–17%
in type- 2 diabetic patients. Undiagnosed thyroid dysfunction
may affect metabolic control and enhance cardiovascular, and
other chronic complication risks in diabetic patients.2 The associa-
tion between SCH and ischemic heart disease has been noticed in
several studies, although the results have been inconsistent3,4
and very few studies have focused on the population with diabetes.Few studies have examined the relationship between subclinical
hypothyroidism and microvascular complications in type 2 dia-
betic patients. To our knowledge, only three studies have investi-
gated the association between SCH and microvascular
complications in Type 2 diabetes. Both Yang et al.5 and Kim et al.6
found that SCH was associated with diabetic retinopathy, although
not with nephropathy. By contrast, Chen et al.7 reported that
patients with Type 2 diabetes and SCH were at increased risk of
nephropathy. Moreover, no study to our knowledge has examined
the prevalence of neuropathy in association with subclinical
hypothyroidism.
Owing to the paucity of data regarding the prevalence of SCH
and its potential association with vascular complications in Type
2 diabetes, this study examined the relationship between SCH
and vascular complications patients with Type 2 diabetes.
Table 1
Comparison between the participants with Euthyroid and SCH in type 2 diabetic
patients regarding the different clinical parameters.
Euthyroid (n = 89) SCH (n = 21) P value
Age (years) 57.78 ± 11.045 63.43 ± 6.95 0.027
Sex (M/F) 40/49 5/16 0.076
Duration of DM(years) 16.64 ± 10.245 22.10 ± 7.77 0.007
BMI (kg/m2) 31.27 ± 6.19 34.2143 ± 7.36 0.092
HbA1c (%) 8.17 ± 1.72 9.15 ± 1.78 0.025
Total cholesterol (mmol/l) 3.85 ± 0.79 5.05 ± 0.83 <0.001
Triglycerides (TG) (mmol/l) 1.54 ± 0.81 1.57 ± 0.50 0.322
LDL cholesterol (mmol/l) 1.89 ± 0.61 2.93 ± 0.73 <0.001
HDL cholesterol (mmol/l) 1.17 ± 0.39 1.41 ± 0.27 0.001
TSH (mU/l) 2.24 ± 0.74 6.37 ± 1.88 <0.001
T4 (pmol/l) 15.49 ± 2.11 14.38 ± 1.66 0.027
UAE 126.43 ± 303.67 434.63 ± 546.92 0.011
Dyslipidemia (%) 97.8 85.7 0.017
HTN (%) 76.4 66.7 0.357
Smoking (%) 24.7 28.6 0.715
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2.1. Patients
Our cross sectional study included 110 patients with type 2 DM
(45 males and 65 females) who were followed at the Diabetes out-
patient Clinics in the state of Kuwait during 6 months period were
subjected to thyroid function test (FT3, FT4, TSH). Patients with
known overt hypothyroidism, known overt or subclinical hyper-
thyroidism and type 1 diabetes mellitus, pregnancy, Postpartum
women, patients with pituitary tumor, thyroid carcinoma or severe
heart, liver, kidney and brain diseases were excluded from the
study.
2.2. Thyroid function tests and definition
Serum thyrotropin (TSH) levels and free thyroxine levels were
measured by chemiluminescent immunoassay. Subclinical
hypothyroidism was defined as an elevated TSH level (>4.2 mIU/
L) and a normal FT4 level (10–23 pmol/L). Euthyroidism was
defined as normal levels of all three parameters: free triiodothy-
ronine, free thyroxine and TSH.
2.3. Clinical examination and laboratory measurements
Relevant data about the patients were collected, including age,
gender, duration of diabetes, history of hypertension, BMI, systolic
and diastolic blood pressure, total cholesterol (TC), triglyceride
(TG), HDL and LDL cholesterol. Glycosylated hemoglobin was mea-
sured using an ion-exchange HPLC (Merck-Hitachi9100).
2.4. Assessment of diabetic microvascular and macrovascular
complication
The patients were diagnosed as having CAD if they had ischemic
changes on a resting electrocardiogram (e.g., abnormal Q waves, ST
segment depression or inverted T waves), a history of angina,
myocardial infarction, or coronary angiography. Diabetic retinopa-
thy was assessed by ophthalmologists and graded according to the
International Clinical Classification of Diabetic Retinopathy.8 Dia-
betic nephropathy was defined as history of diabetes with the
presence of albuminuria, impaired glomerular filtration rate, or
both.9 A single morning urine sample for albuminuria was taken
from subjects and albuminuria defined if equal to or more than
30 mcg/mg Creatinine (mcg/mg Cr).10 Diabetic neuropathy was
diagnosed based on abnormalities detected during neuropathic
screening test (vibration sense testing, temperature sense, pain
perception, monofilament testing and examination of reflexes).
2.5. Statistical analyses
Statistical analyses were performed using SPSS software version
16.0, and results were expressed as mean ± SD. To compare the
means between two groups, Student’s t-test was used for normally
distributed data and the Mann–Whitney test was used for non-
normally distributed data. For categorical comparisons, the chi-
square test was used. A P-value < 0.05 was considered to be statis-
tically significant.
3. Result
Our cross sectional study include 110 patients (45 males and 65
females) with type 2 DM were enrolled in our study with the fol-
lowing characteristics, age, 58.9 ± 10.6 (mean ± SD) years; duration
of DM, 17.7 ± 10.02 years; BMI, 31.8 ± 6.5 kg/m2; HbA1c,8.4 ± 1.8%; TC, 4.08 ± 0.93 mmol/l; triglycerides (TG),
1.55 ± 0.76 mmol/l; HDL-C, 1.22 ± 0.38 mmol/l; LDL-C,
2.09 ± 0.75 mmol/l; TSH, 3.02 ± 1.93 mU/l;T4 (15.28 ± 2.07) pmol/
l; urinary albumin creatinine ratio (185.27 ± 379.66) mcg/mg Cr.
It was found that (105, 95.5%) of patients had dyslipidemia, (43,
39.1%) had diabetic retinopathy, (47, 42.7%) had diabetic
nephropathy, (29, 26.4%) had diabetic neuropathy, (37, 33.6%)
had IHD, (82, 74.5%) were hypertensive and (28, 25.5%) were smo-
ker. Among 110 patients, 21 (19.1%) had SCH. Patients with SCH
were significantly older, with longer duration of diabetes, higher
HbA1c, total cholesterol and LDL-C than euthyroid group. However,
gender (p = 0.076), BMI (p = 0.092), and smoking (P = 0.715) were
not significantly different between the SCH and euthyroid groups
(Table 1). The SCH group had a higher prevalence of dyslipidemia
(p = 0.017), diabetic nephropathy (p = 0.003) diabetic retinopathy
(p = 0.004) and IHD (p = 0.011) than the euthyroid group while
no significant difference in the prevalence of diabetic neuropathy
(p = 0.420) (Table 2 & Fig. 1).
4. Discussion
Vascular endothelial dysfunction is supposed to be an impor-
tant factor in the pathogenesis of microvascular and macrovascular
complications in diabetes. Endothelial dysfunction has also been
described in subclinical hypothyroidism as well as in those with
upper normal TSH values.11,12 The association between microvas-
cular complications and subclinical hypothyroidism and TSH val-
ues has not been comprehensively studied. Among the few
studies done on the subject, the findings have been opposing. This
is a cross-sectional study with a case control analysis which
revealed that The prevalence of subclinical hypothyroidism in type
2 diabetic patients was 19.1%, and this is higher than data reported
from another study done by Gao et al.13 Our present data revealed
that the prevalence of subclinical hypothyroidism was 4.5% in
males and 14.5% in females with Type 2 diabetes. NHANES III, a
population study, reported that the prevalence of subclinical
hypothyroidism was 3.4% in males and 5.8% in females.14 Perros
et al. found that the occurrence of subclinical hypothyroidism
was 3.3% in men and 4.6% in women with Type 2 diabetes.15 The
incidence of subclinical hypothyroidism in our study was greater
than those of both these studies and revealed a dominance of
females. The patients with SCH had a significant longer duration
of diabetes in comparison to the euthyroid group (p = 0.007). In
contrast, Kim et al. didn’t found any significant difference in the
duration of diabetes between euthyroid and SCH patients.6
Although obesity affects hypothalamic-pituitary-thyroid axis
directly or indirectly leading to variations in thyroid function
Table 2
The prevalence of vascular complications in type 2 diabetic patients with and without
SCH.
Euthyroid (n = 89) SCH (n = 21) P value
Retinopathy (%) 32.6 66.7 0.004
Nephropathy (%) 36 71.4 0.003
Neuropathy (%) 24.7 33.3 0.420












Figure 1. The prevalence of vascular complications in type 2 diabetes patients with
and without subclinical hypothyroidism (SCH).
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diabetic patients and euthyroid group (P = 0.092). In this cross-
sectional analysis of type 2 diabetes mellitus, subclinical hypothy-
roidism was associated with a higher frequency of microvascular
(diabetic nephropathy, and retinopathy) and macrovascular com-
plication (IHD). Our result differed from those of Chen et al. study
which showed that type 2 diabetic patients with subclinical
hypothyroidism are associated with an increased risk of nephropa-
thy and cardiovascular events, but not with retinopathy.7 While
Kim et al. showed that SCH was associated with sight-
threatening diabetic retinopathy, but not associated with diabetic
nephropathy. However, he did not analyze the relationship
between SCH and prevalence of macrovascular complications.
kim et al. explained the link between SCH and diabetic retinopathy
by insulin resistance that was higher in the SCH than the euthyroid
group.6 In contrast to, Gao et al. concluded that there is no associ-
ation between subclinical hypothyroidism, and microvascular
complications in type 2 diabetes.17 It is known that thyroid hor-
mone plays an important role in kidney growth and preservation
of many of its functions.18,19 In other words, the glomerular filtra-
tion rate in hypothyroid patients is approximately one-third lower
than the corresponding values in euthyroid individuals.20 Suher
et al. suggested that subjects with hypothyroidism may have
increased urinary albumin excretion rate21 which came consis-
tence to our result as there was a significant increase in the mean
of albuminuria in patients with SCH. Moreover, a study done in
Japan by Yasuda et al., subclinical hypothyroidism was associated
with albuminuria in type 2 diabetic patients and the TSH level
was found to be an independent risk factor for the presence of
albuminuria.22 In our study, the prevalence of IHD was signifi-
cantly higher in patients with SCH than in patients without SCH.
Jia et al. provides evidence that SCH in patients with Type 2 dia-
betes is associated with a high prevalence of CHD.23 This issue
can be explained by Overt thyroid hormone deficiency which leads
to increases in total cholesterol and LDL–C levels24 which is evi-
dent in our result. Also, thyroid hormone deficiency can also dam-age vascular function directly.25,26 Furthermore, several
researchers have stated that SCH impairs the relaxation of vascular
smooth muscle cells, thereby inducing increased arterial stiffness
and systemic vascular resistance25, as well as changes in endothe-
lial function due to decreased nitric oxide availability.26,27
Endothelial dysfunction in SCH could be due to inflammation.28 A
higher levels of IL-6, TNF-alpha and high-sensitive C-reactive pro-
tein (hs-CRP) in patients with SCH were found. In addition, a low
grade chronic inflammation in patients with SCH can also be
explained by the autoimmune thyroiditis.29 Although, Hollander
et al. demonstrated that renal function was better in 32 patients
with hypothyroidism after thyroxine treatment,30 our study was
observational, and it does not follow the impact of treatment of
subclinical hypothyroidism on risk reduction of diabetic vascular
complication. Whether the management of patients with subclini-
cal hypothyroidism affects important cardiovascular outcomes
remains an unanswered question.31,32 Chu and Crapo suggested
that there was a little or no benefit of thyroxine therapy in most
patients with subclinical hypothyroidism.33 However, they also
concluded that thyroxine treatment may be beneficial in selected
patients with certain clinical circumstances.34
5. Conclusion
SCH is a common endocrine disorder in patients with Type 2
diabetes. It could be associated with a higher prevalence of vascu-
lar complication in type 2 diabetes. But, we could not prove a rela-
tion between SCH and diabetic neuropathy.
Recommendation
Routine screening of thyroid function in type 2 diabetic patients
is necessary; and the treatment of subclinical hypothyroidism
might have a considerable effect on the prevention or clinical
course of vascular complications in type 2 diabetes.
Limitation of the study
Firstly, our study was observational, and it does not follow the
effect of treatment of subclinical hypothyroidism on risk reduction
of diabetic vascular complication. Secondly, there is a need for fur-
ther study with a case matched control to be compared to the
major variables like age, duration of DM, glycemic control, and
lipid profile. Thirdly, the screening tests for diabetic nephropathy
were done once; ideally these should be repeated for confirmation.
Finally, we did not evaluate the other macrovascular complications
of diabetes such as cerebrovascular and peripheral vascular
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